Gonococcal Isolate Surveillance Project (GISP) Profiles, 2019
STD Surveillance Report 2019
Requires Adobe Reader.
Figure A – Age of GISP Participants, in Years, 2019
Figure B – Race/Ethnicity of GISP Participants, 2019
Figure C – Percentage of GISP Participants Identifying as Men Who Have Sex with Men, 2000-2019
Figure D – Primary Antimicrobial Drug Used to Treat Gonorrhea among GISP Participants, 2019
Figure E – Secondary Antimicrobial Drug Used to Treat Gonorrhea among GISP Participants, 2019
Figure F – Percentage of Isolates with Penicillin, Tetracycline, and Ciprofloxacin Resistance, 2019
Figure G – Distribution of Ceftriaxone Minimum Inhibitory Concentrations (MICs) among GISP Isolates, 2015-2019
Figure H – Distribution of Cefixime Minimum Inhibitory Concentrations (MICs) among GISP Isolates, 2015-2019
Figure I – Percentage of Isolates with Intermediate Resistance or Resistance to Ciprofloxacin, 2000-2019
Figure J – Distribution of Azithromycin Minimum Inhibitory Concentrations (MICs) among GISP Isolates, 2015-2019
The Gonococcal Isolate Surveillance Project (GISP), a national sentinel surveillance system, was established in 1986 to monitor trends in antimicrobial susceptibilities of Neisseria gonorrhoeae strains in the United States among selected sexually transmitted diseases (STD) clinics in approximately 25-30 GISP sentinel sites.
Annual reports were published for the years 1998–2007. Starting in 2008, site-specific GISP profiles have been published online each year.
The following site-specific profiles consist of figures depicting the demographic and clinical data of the men with gonorrhea enrolled in GISP and the antimicrobial susceptibility results of the Neisseria gonorrhoeae isolates submitted.